4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Jul-31-26 | Initiated | B. Riley Securities | Buy | $37 |
| Jan-28-26 | Resumed | Barclays | Overweight | $33 |
| Nov-07-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight | |
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform | $40 → $15 |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight | $8 |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Apr-15-24 | Initiated | Barclays | Overweight | $459 |
| Apr-15-24 | Initiated | Barclays | Overweight | $45 |
| Feb-07-24 | Resumed | Goldman | Buy | $81 |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform | $25 |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight | $32 |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform | $24 |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy | $30 |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform | $50 |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy | $36 |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy | $12 → $68 |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform | $12 |
| Jun-22-22 | Initiated | Jefferies | Buy | $22 |
| Jan-04-22 | Initiated | SVB Leerink | Outperform | $30 |
| Jan-05-21 | Initiated | Goldman | Neutral | $44 |